Keloid Formation in Athletes: Pathophysiology, Biomechanical Risk Factors, Psychosocial Burden, and Current Therapeutic Approaches
DOI:
https://doi.org/10.12775/QS.2026.55.71628Keywords
keloids, scar formation, sports medicine, fibroblasts, wound healing, psychosocial impactAbstract
Keloids represent a chronic dermatological condition resulting from abnormal wound healing and excessive proliferation of fibrotic tissue. These lesions may lead not only to physical symptoms such as pain, pruritus, and restricted mobility, but also to significant psychosocial consequences that adversely affect patients’ quality of life. In recent years, increasing attention has been directed toward the molecular mechanisms underlying keloid formation, including dysregulation of fibroblast activity, abnormal signaling pathway modulation, and the influence of genetic and biomechanical factors.
Athletes constitute a particularly vulnerable group with regard to the development of pathological scars. Intense physical activity, frequent skin injuries, repetitive microtrauma, and surgical procedures commonly performed in sports medicine may increase the risk of keloid formation. Furthermore, scar lesions may negatively affect tissue function, training comfort, physical performance, and the psychological well-being of athletes.
The aim of this paper is to present current knowledge regarding the molecular mechanisms involved in keloid formation, biomechanical risk factors observed in athletes, contemporary therapeutic approaches, and the psychosocial consequences of these lesions in the context of sports medicine.
References
1. Mishra T, Wairkar S. Pathogenesis, attenuation, and treatment strategies for keloid management. Tissue Cell. 2025 Jun;94:102800.
2. Ekstein SF, Wyles SP, Moran SL, Meves A. Keloids: a review of therapeutic management. Int J Dermatol. 2021 Jun;60(6):661–71.
3. Trace AP, Enos CW, Mantel A, Harvey VM. Keloids and hypertrophic scars: A spectrum of clinical challenges. Am J Clin Dermatol. 2016 Jun;17(3):201–23.
4. Kim HJ, Kim YH. Comprehensive Insights into Keloid Pathogenesis and Advanced Therapeutic Strategies. Int J Mol Sci. 2024 Aug 12;25(16).
5. Sitaniya S, Subramani D, Jadhav A, Sharma YK, Deora MS, Gupta A. Quality-of-life of people with keloids and its correlation with clinical severity and demographic profiles. Wound Repair Regen. 2022 May;30(3):409–16.
6. Kassi K, Kouame K, Kouassi A, Allou A, Kouassi I, Kourouma S, et al. Quality of life in black African patients with keloid scars. Dermatol Reports. 2020 Sep 23;12(2):8312.
7. Barone N, Safran T, Vorstenbosch J, Davison PG, Cugno S, Murphy AM. Current advances in hypertrophic scar and keloid management. Semin Plast Surg. 2021 Aug;35(3):145–52.
8. Ojeh N, Bharatha A, Gaur U, Forde AL. Keloids: Current and emerging therapies. Scars, Burns & Healing. 2020 Aug 10;6:2059513120940499.
9. Mbiine R, Wayengera M, Kiwanuka N, Munabi IG, Muwonge H, Nakanwagi C, et al. Description of clinical and histopathological characteristics of keloids in a sub-Saharan African population. Skin Health and Disease. 2025 Oct;5(5):326–43.
10. Fang X, Wang Y, Chen H, Yan Z, Jin S, Wu Y, et al. Hypertrophic scarring and keloids: epidemiology, molecular pathogenesis, and therapeutic interventions. MedComm. 2025 Oct 4;6(10):e70381.
11. Mathew M, DiBartolomeo G, Stone RC. Biopsychosocial impact of keloids on quality of life. JAAD Reviews. 2024 Dec;2:13–9.
12. Walliczek U, Engel S, Weiss C, Aderhold C, Lippert C, Wenzel A, et al. Clinical outcome and quality of life after a multimodal therapy approach to ear keloids. JAMA Facial Plast Surg. 2015;17(5):333–9.
13. Berman B, Maderal A, Raphael B. Keloids and hypertrophic scars: pathophysiology, classification, and treatment. Dermatol Surg. 2017 Jan;43 Suppl 1:S3–18.
14. Lee HJ, Jang YJ. Recent understandings of biology, prophylaxis and treatment strategies for hypertrophic scars and keloids. Int J Mol Sci. 2018 Mar 2;19(3).
15. Ogawa R. Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis. Int J Mol Sci. 2017 Mar 10;18(3).
16. Limandjaja GC, Niessen FB, Scheper RJ, Gibbs S. The keloid disorder: heterogeneity, histopathology, mechanisms and models. Front Cell Dev Biol. 2020 May 26;8:360.
17. Andrews JP, Marttala J, Macarak E, Rosenbloom J, Uitto J. Keloids: The paradigm of skin fibrosis - Pathomechanisms and treatment. Matrix Biol. 2016 Apr;51:37–46.
18. Lee C-C, Tsai C-H, Chen C-H, Yeh Y-C, Chung W-H, Chen C-B. An updated review of the immunological mechanisms of keloid scars. Front Immunol. 2023 Mar 22;14:1117630.
19. Zakrzewski B, Narbutt J, Noweta M, Sobolewska-Sztychny D, Borodacz J, Zakrzewska A, et al. Molecular mechanisms of keloid development. Forum Dermatol. 2025 Dec 19;11(4):166–73.
20. Merlino L, Dominoni M, Pano MR, Pasquali MF, Senatori R, Zino G, et al. Recent progress in keloid mechanism and treatment: A comprehensive review. Biomedicines. 2025 Sep 16;13(9).
21. Liu J, Yan J, Qi S, Zhang J, Zhang X, Zhao Y. The PI3K/AKT/mTOR pathway in scar remodeling and keloid formation: mechanisms and therapeutic perspectives. Front Pharmacol. 2025 Dec 4;16:1678953.
22. Yin Q, Wolkerstorfer A, Lapid O, Niessen FB, Van Zuijlen PPM, Gibbs S. The JAK-STAT pathway in keloid pathogenesis: a systematic review with qualitative synthesis. Exp Dermatol. 2023 May;32(5):588–98.
23. Feng F, Liu M, Pan L, Wu J, Wang C, Yang L, et al. Biomechanical regulatory factors and therapeutic targets in keloid fibrosis. Front Pharmacol. 2022 May 9;13:906212.
24. Betarbet U, Blalock TW. Keloids: A review of etiology, prevention, and treatment. J Clin Aesthet Dermatol. 2020 Feb 1;13(2):33–43.
25. Walsh LA, Wu E, Pontes D, Kwan KR, Poondru S, Miller CH, et al. Keloid treatments: an evidence-based systematic review of recent advances. Syst Rev. 2023 Mar 14;12(1):42.
26. van Leeuwen MCE, Bulstra AEJ, Ket JCF, Ritt MJPF, van Leeuwen PAM, Niessen FB. Intralesional cryotherapy for the treatment of keloid scars: evaluating effectiveness. Plast Reconstr Surg Glob Open. 2015 Jun;3(6):e437.
27. Leszczynski R, da Silva CA, Pinto ACPN, Kuczynski U, da Silva EM. Laser therapy for treating hypertrophic and keloid scars. Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD011642.
28. Foppiani JA, Khaity A, Al-Dardery NM, Hasan MT, El-Samahy M, Lee D, et al. Laser Therapy in Hypertrophic and Keloid Scars: A Systematic Review and Network Meta-analysis. Aesthetic Plast Surg. 2024 Oct;48(19):3988–4006.
29. Bijlard E, Kouwenberg CAE, Timman R, Hovius SER, Busschbach JJV, Mureau MAM. Burden of Keloid Disease: A Cross-sectional Health-related Quality of Life Assessment. Acta Derm Venereol. 2017 Feb 8;97(2):225–9.
30. Austin E, Koo E, Jagdeo J. The cellular response of keloids and hypertrophic scars to botulinum toxin A: A comprehensive literature review. Dermatol Surg. 2018 Feb;44(2):149–57.
31. Quong WL, Hadžimustafić N, Borkhoff CM, Drucker AM, Fish JS. Associations between skin scars and body image - A systematic review and meta-analysis. Soc Sci Med. 2026 Mar;393:118841.
32. Huang Y, Xu S, Wu Y, Gu Z, Dong C, Zhang L, et al. Coping tendencies play partial mediating role between social support and anxiety/depression among Chinese keloid patients. Front Psychiatry. 2025 Oct 15;16:1543484.
33. Amici JM, Taieb C, Le Floc’h C, Demessant A, Seité S, Cogrel O. The impact of visible scars on well-being and quality of life: An international epidemiological survey in adults. J Eur Acad Dermatol Venereol. 2023 Mar;37 Suppl 3:3–6.
34. Ogawa R. The most current algorithms for the treatment and prevention of hypertrophic scars and keloids: A 2020 update of the algorithms published 10 years ago. Plast Reconstr Surg. 2022 Jan 1;149(1):79e–94e.
35. Tian F, Jiang Q, Chen J, Liu Z. Silicone gel sheeting for treating keloid scars. Cochrane Database Syst Rev. 2023 Jan 3;1(1):CD013878.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 The Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 85
Number of citations: 0